|Printable version||E-mail this to a friend|
Zika virus infection: plasma- and urine-derived medicines safe to use
Manufacturing processes for these products successfully inactivate or remove virus.
Assessments carried out by the European Medicines Agency (EMA) and competent authorities in the EU Member States have confirmed that there is no increased risk of contamination with the Zika virus for patients who take plasma-derived or urine-derived medicines.
Plasma-derived medicines are manufactured from human blood. They are used to treat and prevent serious diseases and include coagulation factors (treatments which help blood to clot) and immunoglobulins (proteins used in patients who need more antibodies in their blood to help fight infections and other diseases). Urine-derived products are manufactured from pooled human urine and include certain hormone-based treatments and urokinase products (medicines used to break up blood clots).
These medicines are produced from body fluids, which might be sourced in parts of the world where the Zika virus is prevalent. EU regulators sought reassurance that there is no risk of the virus contaminating the final product and thus affecting the patients taking it if the plasma or urine came from donors who had contracted the Zika virus.
EMA’s Committee for Medicinal Products for Human Use (CHMP) has addressed the potential risk from Zika virus for plasma-derived medicinal products. The CMDh has coordinated the assessment by EU Member States on the potential risk from Zika virus for urine-derived medicinal products.
The CHMP concluded at its meeting last week that the manufacturing processes used for plasma-derived products, including for example the solvent/detergent method to inactivate viruses, pasteurisation (liquid heat inactivation) and virus filtration, inactivate or remove the Zika virus from the finished product. The CHMP therefore considered that no additional safety measures such as the testing or exclusion of certain plasma donors was necessary.
Concerning urine-derived products, the CMDh, following the assessment of the data, concluded that the manufacturing processes for these products contain complementary steps with inactivation/removal capacity for enveloped viruses, which are considered sufficient for Zika virus safety of these products. Additional safety measures such as the screening of urine donors or donations or the deferral of donors returning from affected areas are not considered necessary.
The findings from these assessments on the viral safety of plasma-derived and urine-derived medicines are available in a report from the CHMP’s Biologics Working Party(BWP) published yesterday.
- The CMDh is a medicines regulatory body representing the European Union (EU) Member States.
- The Biologics Working Party (BWP) provides recommendations to EMA’s scientific committees on all matters relating directly or indirectly to quality and safety aspects relating to biological and biotechnological medicines.
- The BWP recommendation on plasma-derived products is in line with the guidance published in July 2016 by the European Centre for Disease Prevention and Control (ECDC) entitled “Zika virus and safety of substances of human origin - A guide for preparedness activities in Europe”.
|Zika virus infection: plasma- and urine-derived medicines safe to use||(English only)||21/09/2016|
Latest News from
EU budget: "We have to deal with the problem caused by Brexit"28/10/2016 10:32:00
The outcome of the Brexit referendum will already affect the EU's budget for next year as the value of the British pound is dropping. What should be done about it?
Pesticide residues in food: risk to consumers remains low28/10/2016 10:10:00
97% of food samples collected in the European Union are free of pesticide residues or contain traces that are within legal limits. The conclusion is part of EFSA’s latest annual report on pesticide residues in food.
EU-LAC Foundation: constitutive agreement signed28/10/2016 09:25:00
The EU and the Community of Latin American and Caribbean States (CELAC) signed an agreement establishing the EU - Latin America and the Caribbean Foundation, the EU-LAC Foundation, as an international organisation on 25 October in Santo Domingo, Dominican Republic.
New search page for periodic safety update report single assessments (PSUSAs)28/10/2016 07:10:00
The European Medicines Agency (EMA) has published a new search page on its website, helping users to find the outcomes of PSUSA procedures for active substances or combinations of active substances contained in nationally authorised medicines.
More funds needed for youth and jobs in 2017 to honour EU’s pledges, say MEPs27/10/2016 16:42:00
Parliament demanded more funds, to help young people into jobs, boost economic growth and assist third countries with a view to mitigating the migration crisis, in a plenary vote on Wednesday. MEPs reversed all the Council’s proposed cuts in the draft EU budget for 2017.